PowerShares DWA Healthcare Momentum ETF

Most Recent

  • uploads///md pm
    Earnings Report

    MEDNAX Revenue and Income Rose After 3Q15 Results

    MEDNAX’s YTD price movement was a mix of rises and falls in 2015. After the earnings report, MEDNAX fell 3.4% to close at $71.3 per share as of October 29, 2015.

    By Gabriel Kane
  • uploads///Chart  NMDA
    Company & Industry Overviews

    What Are Sage Therapeutics’ Receptor-Based Products?

    Sage Therapeutics (SAGE) is focused on the development of the products for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///gks coo
    Earnings Report

    Cooper Companies Reported Mixed 2Q15 Results

    Cooper Companies (COO) is a $7.33 billion global medical device company. The company has two business units, CooperVision and CooperSurgical.

    By Gabriel Kane
  • uploads///Ignyta risks
    Company & Industry Overviews

    Ignyta and Its Key Risks in 2018

    In October 2017, Ignyta (RXDX) raised $150 million by issuing 10 million shares of its common stock.

    By Kenneth Smith
  • uploads///Graph naglazyme
    Company & Industry Overviews

    Naglazyme: One of the Costliest Drugs in the United States

    The wholesale cost per patient for Naglazyme is around $485,747 per year. The drug has been effective in improving walking and stair-climbing capacity.

    By Jillian Dabney
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.